2018年至2021年间，希腊一家三级保健大学医院因罕见的非念珠菌酵母菌引起的真菌病

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2023-08-01 DOI:10.1016/j.mycmed.2023.101386

Anastasia Spiliopoulou , Alexandra Lekkou , Georgia Vrioni , Lydia Leonidou , Massimo Cogliati , Myrto Christofidou , Markos Marangos , Fevronia Kolonitsiou , Fotini Paliogianni

{"title":"2018年至2021年间，希腊一家三级保健大学医院因罕见的非念珠菌酵母菌引起的真菌病","authors":"Anastasia Spiliopoulou , Alexandra Lekkou , Georgia Vrioni , Lydia Leonidou , Massimo Cogliati , Myrto Christofidou , Markos Marangos , Fevronia Kolonitsiou , Fotini Paliogianni","doi":"10.1016/j.mycmed.2023.101386","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Non-<em>Candida</em> yeasts, although rare, are increasingly encountered and recognized as a growing threat.</p></div><div><h3>Methods</h3><p>Cases of bloodstream infections (BSIs) due to non-<em>Candida</em> yeasts (NCYs) during the last four years (2018–2021) are presented.</p></div><div><h3>Results</h3><p>During the study period, 16 cases caused by non-<em>Candida</em> yeasts out of 400 cases of yeast BSIs were recorded, corresponding to an incidence of 4%. Yeasts that were isolated included <em>Cryptococcus</em> spp (4 isolates-25%), <em>Rhodotorula mucilaginosa</em> (2 isolates-12.5%), <em>Trichosporon asahii</em> (7 isolates-43.75%) and <em>Saccharomyces cerevisiae</em> (3 isolates-18.75%). Predisposing factors involved mostly hematological malignancies, long term hospitalization or major surgical interventions. Most isolates, 15 out of 16 were susceptible to amphotericin B. Voriconazole was the most active azole in vitro. All isolates, except <em>Saccharomyces</em> spp., were resistant to echinocandins.</p></div><div><h3>Discussion</h3><p>Early recognition of rare yeasts as causative agents of BSIs and prompt initiation of appropriate treatment based on current guidelines and expertise remain crucial in efficient patient management.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101386"},"PeriodicalIF":2.2000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fungemia due to rare non-Candida yeasts between 2018 and 2021 in a Greek tertiary care university hospital\",\"authors\":\"Anastasia Spiliopoulou , Alexandra Lekkou , Georgia Vrioni , Lydia Leonidou , Massimo Cogliati , Myrto Christofidou , Markos Marangos , Fevronia Kolonitsiou , Fotini Paliogianni\",\"doi\":\"10.1016/j.mycmed.2023.101386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Non-<em>Candida</em> yeasts, although rare, are increasingly encountered and recognized as a growing threat.</p></div><div><h3>Methods</h3><p>Cases of bloodstream infections (BSIs) due to non-<em>Candida</em> yeasts (NCYs) during the last four years (2018–2021) are presented.</p></div><div><h3>Results</h3><p>During the study period, 16 cases caused by non-<em>Candida</em> yeasts out of 400 cases of yeast BSIs were recorded, corresponding to an incidence of 4%. Yeasts that were isolated included <em>Cryptococcus</em> spp (4 isolates-25%), <em>Rhodotorula mucilaginosa</em> (2 isolates-12.5%), <em>Trichosporon asahii</em> (7 isolates-43.75%) and <em>Saccharomyces cerevisiae</em> (3 isolates-18.75%). Predisposing factors involved mostly hematological malignancies, long term hospitalization or major surgical interventions. Most isolates, 15 out of 16 were susceptible to amphotericin B. Voriconazole was the most active azole in vitro. All isolates, except <em>Saccharomyces</em> spp., were resistant to echinocandins.</p></div><div><h3>Discussion</h3><p>Early recognition of rare yeasts as causative agents of BSIs and prompt initiation of appropriate treatment based on current guidelines and expertise remain crucial in efficient patient management.</p></div>\",\"PeriodicalId\":14824,\"journal\":{\"name\":\"Journal de mycologie medicale\",\"volume\":\"33 3\",\"pages\":\"Article 101386\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal de mycologie medicale\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1156523323000306\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MYCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523323000306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

非念珠菌虽然罕见，但越来越多地遇到并认识到它是一种日益增长的威胁。方法分析近4年(2018-2021年)非念珠菌(NCYs)引起的血液感染(bsi)病例。结果400例酵母菌性脑损伤中，非念珠菌性16例，发病率为4%。分离到的酵母菌包括隐球菌(4株)(占25%)、粘液红酵母(2株)(占12.5%)、asahitrichosporon(7株)(占43.75%)和酿酒酵母(3株)(占18.75%)。易感因素主要包括血液系统恶性肿瘤、长期住院或重大手术干预。大多数分离株对两性霉素b敏感，16株中有15株对两性霉素b敏感。除Saccharomyces spp外，其余菌株均对棘白菌素耐药。早期认识到罕见酵母菌是脑损伤的病原体，并根据现行指南和专业知识及时开始适当的治疗，对于有效的患者管理仍然至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Fungemia due to rare non-Candida yeasts between 2018 and 2021 in a Greek tertiary care university hospital

Introduction

Non-Candida yeasts, although rare, are increasingly encountered and recognized as a growing threat.

Methods

Cases of bloodstream infections (BSIs) due to non-Candida yeasts (NCYs) during the last four years (2018–2021) are presented.

Results

During the study period, 16 cases caused by non-Candida yeasts out of 400 cases of yeast BSIs were recorded, corresponding to an incidence of 4%. Yeasts that were isolated included Cryptococcus spp (4 isolates-25%), Rhodotorula mucilaginosa (2 isolates-12.5%), Trichosporon asahii (7 isolates-43.75%) and Saccharomyces cerevisiae (3 isolates-18.75%). Predisposing factors involved mostly hematological malignancies, long term hospitalization or major surgical interventions. Most isolates, 15 out of 16 were susceptible to amphotericin B. Voriconazole was the most active azole in vitro. All isolates, except Saccharomyces spp., were resistant to echinocandins.

Discussion

Early recognition of rare yeasts as causative agents of BSIs and prompt initiation of appropriate treatment based on current guidelines and expertise remain crucial in efficient patient management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.